Sunday, 5 October 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 05 October 2025
News

Is this popular drug on thin ice?

 Posted 30 September 2025 PM

Makers of the P2Y12 inhibitor clopidogrel will be hoping for a change in clinical guidelines and a big leap in sales after a study showed it to be a more effective blood thinner than aspirin.

The meta-analysis of seven randomised trials, involving almost 29,000 patients, compared clopidogrel monotherapy with aspirin monotherapy in patients with established coronary artery disease (CAD) who had discontinued or never started dual antiplatelet therapy (a P2Y12 inhibitor in combination with aspirin).

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (25)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (2)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.